AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results - Concepedia

Concepedia

Publication | Closed Access

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

51

Citations

0

References

2021

Year

David A. Sallman, Adam Asch, Suman Kambhampati, Monzr Al Malki, Joshua F. Zeidner, William B. Donnellan, Daniel Lee, Paresh Vyas, Deepa Jeyakumar, Gabriel N. Mannis,

Clinical Lymphoma Myeloma & Leukemia

Phase 1BOncologyImmunologyAml PatientsImmune Checkpoint InhibitorImmunotherapyMedicine

No additional data available for this publication yet. Check back later!